RPRX vs XOMA
RPRX: Royalty Pharma is the leading financier of pharmaceutical innovation, providing capital in exchange for long-term royalty streams on top-tier commercial drug therapies. XOMA: A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights across a diversified 120+ asset portfolio spanning oncology, rare disease, and specialty therapeutics.
Side-by-side fundamentals
| Metric | RPRX | XOMA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.72 | $40.17 | |
| Market cap as of 2026-07-23 | $33.8B | $710M | |
| P/E as of 2026-07-23 | 40.88 | 21.00 | XOMA lower |
| PEG as of 2026-07-23 | 3.37 | n/a | |
| Net margin as of 2026-07-23 | +33.9% | +69.6% | XOMA higher |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | +65.1% | +61.3% | RPRX higher |
| ROE as of 2026-07-23 | +12.7% | +32.4% | XOMA higher |
| ROA as of 2026-07-23 | +4.3% | +13.1% | XOMA higher |
| Debt / equity as of 2026-07-23 | 1.30 | 0.91 | XOMA lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.8% | +13.2% | XOMA higher |
| Revenue CAGR (3y) SEC XBRL | +2.1% | +105.3% | XOMA higher |
| Dividend yield as of 2026-07-23 | +1.6% | +0.8% | RPRX higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.43 | 0.88 | |
| 1-year return as of 2026-07-22 close | +62.7% | +48.0% | RPRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.